IDXG INTERPACE BIOSCIENCES, INC.

MIXED Impact: 6/10 8-K
Horizon weeks Filed Apr 1, 2026 Processed 2mo ago SEC 0001493152-26-014654
earnings-rerun-backfill
Latest settled — T+20d
IDXG ▲ +1.12% at T+20d
NEUTRAL call ✓ call won +1.12% · α vs SPY -8.75% · entry $1.96 → $1.98
Next anchor: T+60d in 14d
Last close $1.60 (close Jun 12) · -18.28% from $1.96 entry
Entry anchored
Apr 1, 2026
via day open
T+1d
+0.61%
call +0.61% · α +0.14%
$1.97
settled 2mo ago
T+5d
+17.47%
call +17.47% · α +13.85%
$2.30
settled 2mo ago
T+20d
+1.12%
call +1.12% · α -8.75%
$1.98
settled 7w ago
T+60d
—
call — · α —
—
in 14d

Price Chart

Loading chart...

Executive Summary

Interpace Biosciences reported full-year 2025 revenue of $38.7 million and income from continuing operations of $25.0 million, driven by a 21% year-over-year increase in thyroid revenue and a one-time $21.2 million tax benefit from the release of a deferred tax valuation allowance. The company completed its transition to a thyroid-only diagnostics model after discontinuing PancraGEN.

Key Financial Metrics

Free Cash Flow
$5.5M
Gross Margin
62%

Actionable Insight

Monitor next quarter for thyroid revenue growth sustainability and whether the company can maintain profitability without the one-time tax benefit. The pro forma comparison suggests underlying business improvement.

Key Facts

  • Full-year 2025 revenue was $38.7 million, down 18% from $46.9 million in 2024
  • Income from continuing operations was $25.0 million, including a one-time $21.2 million tax benefit
  • Thyroid revenue grew 21% year-over-year in 2025
  • Company transitioned to thyroid-only diagnostics after discontinuing PancraGEN in May 2025
  • Pro forma 2024 revenue (thyroid-only) was $33.2 million, making 2025 revenue a 17% increase

Financial Impact

Revenue decreased 18% YoY but increased 17% on a pro forma thyroid-only basis; $21.2 million one-time tax benefit inflated earnings

revenuenet incometax expense

Risk Factors

  • Heavy reliance on one-time tax benefit inflates profitability
  • Revenue decline on reported YoY basis despite pro forma improvement
  • Transition risk from discontinuing PancraGEN product line

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-014654
Document: form8-k.htm0001493152-26-014654
Document: 0001493152-26-014654-index-headers.html0001493152-26-014654
Document: 0001493152-26-014654-index.html0001493152-26-014654
Document: 0001493152-26-014654.txt0001493152-26-014654
8-K Data (Synthetic)0001493152-26-014654

US Market Status

Market Closed — Opens in 5h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access